Scroll back to top

Posted October 1, 2019

Discontinuation Of Tests MET22 And MET25, Folate Receptor Antibody Assay, In Plasma/Serum And CSF

Due to a manufacturer reagent change, MNG will discontinue testing for Folate Receptor Antibodies.

Alternative diagnostic testing is available at MNG for cerebral folate deficiency, characterized by a lack of B-vitamin folate (vitamin B-9) in the brain; see 5-methyltetrahydrofolate analysis in CSF (NC01) and FOLR1 gene sequencing (MOL166).

MNG will discontinue MET22 in plasma/serum and MET25 in CSF; testing will not be performed on samples received after October 31, 2019.

Related News

Amino Acid Assay Update

Effective July 27, 2020 the MNG amino acid assays, Test Codes MET01, MET02, and MET03 will be performed by our Parent company, LabCorp, in its Burlington, NC laboratory. 

MNG Moves To Exome-Backbone Sequencing

MNG is excited to announce the launch of 15 new next-generation sequencing (NGS) panels. In an effort to meet the needs of our clients, we are introducing a Comprehensive Hearing Loss panel and a Comprehensive Vision Loss & Eye Disorders panel, both including mtDNA analysis.

Discontinuation Of Test NC09

Succinic semialdehyde dehydrogenase (SSADH) deficiency is a disorder affecting GABA metabolism. This disorder is generally diagnosed by the finding of elevated levels of gamma hydroxybutyric acid (GHB) in urine using standard organic acid analysis.